SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Revenue reduced marginally to stand at Rs. 17855.44 millions during the quarter ended March 2022. The figure stood at Rs. 18503.69 millions during the year-ago period.The Net Profit of the company slipped to Rs. 2055.97 millions from Rs. 3417.75 millions, a decline of -39.84% on QoQ basis.Operating profit for the quarter ended March 2022 decreased to 3405.67 millions as compared to 4728.67 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 17855.44 18503.69 -3.50 81415.81 75679.33 7.58 81415.81 75679.33 7.58
Other Income 1789.82 1168.58 53.16 6146.28 3962.37 55.12 6146.28 3962.37 55.12
PBIDT 3405.67 4728.67 -27.98 23028.49 22865.78 0.71 23028.49 22865.78 0.71
Interest 740.10 625.07 18.40 2360.41 2658.98 -11.23 2360.41 2658.98 -11.23
PBDT 2665.57 4103.60 -35.04 24971.41 20945.72 19.22 24971.41 20945.72 19.22
Depreciation 417.72 370.00 12.90 1596.95 1508.15 5.89 1596.95 1508.15 5.89
PBT 2247.85 3733.60 -39.79 23374.46 19437.57 20.25 23374.46 19437.57 20.25
TAX 191.88 315.85 -39.25 3396.57 2943.10 15.41 3396.57 2943.10 15.41
Deferred Tax -210.77 -373.44 -43.56 -714.21 -493.08 44.85 -714.21 -493.08 44.85
PAT 2055.97 3417.75 -39.84 19977.89 16494.47 21.12 19977.89 16494.47 21.12
Equity 282.17 282.17 0.00 282.17 282.17 0.00 282.17 282.17 0.00
PBIDTM(%) 19.07 25.56 -25.36 28.29 30.21 -6.38 28.29 30.21 -6.38

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×